A MULTICENTER NON-INFERIORITY STUDY OF EFFICACY AND SAFETY OF GENERIC IMATINIB IN CHRONIC MYELOID LEUKEMIA – FINAL ANALYSIS

Aim: This study aimed to evaluate efficacy and safety of generic imatinib (IM) compared to branded imatinib (Glivec) in chronic myeloid leukemia. The primary end-point was the achievement of a major molecular response (MMR) at 12 months and safety. Secondary end-points included response evaluation,...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	KBB Pagnano, ECM Miranda, I Bendit, F Seguro, M Conchon, NN Gonçalves, GH Magalhães, N Clementino, D Borducchi, N Andari, A Coelho, I Luise, L Fogliatto, J Bortolini, R Centrone, C Boquimpani, CA Souza
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Elsevier 2021-10-01
Cyfres:	Hematology, Transfusion and Cell Therapy
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S2531137921003606
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!